Text or WhatsApp Richard at (808) 600-9260
Lion crestHealthcareInvestmentBanking.com

Healthcare Practice Valuation Calculator: 2026 EBITDA Multiples, Escrow and Cash at Close

A healthcare practice sells for adjusted EBITDA times a multiple. The seller then receives equity value less escrow, earnout and rollover. For 2026, FOCUS Investment Banking's dashboard gives 8.8x for multi-specialty practices with $5 to $10 million of EBITDA, a single published benchmark figure. Its dermatology benchmarks run from 3x to 5x for solo practices under $2 million of revenue up to 12x to 15x for platforms above $50 million. SRS Acquiom's 2025 deals across all sectors had a median total escrow of 11.1% of transaction value without RWI and 2.8% with it. Enter adjusted EBITDA and a multiple range below. The calculator returns enterprise and equity value, and the tables carry it to cash at close.

Estimate only. Educational, not investment advice.

Data as of November 20, 2026. Sources: FOCUS Investment Banking (2026 dashboard and 2026 dermatology benchmarks, published benchmark figures with no stated sample), Aswath Damodaran at NYU Stern (US listed companies, January 2026), SRS Acquiom (2025 deals, all sectors), PESP via Becker's ASC Review (2025 outpatient deals), Kaufman Hall via Becker's Hospital Review (hospital announcements through Q3 2026) and CMS (2024 national health spending). Every worked example uses invented inputs, and every derived figure is our arithmetic.

What the Calculator Counts, and What It Leaves to You

Inputs

Input What to enter How the tool uses it
Revenue and reported EBITDA margin Trailing 12 months, the same period the buyer uses. Enter the margin exactly as reported, with no adjustments. Reported EBITDA = revenue x margin
One-time costs to add back Documented, non-recurring costs inside reported EBITDA, such as a one-off legal bill Added to reported EBITDA once
Number of owners Physicians or partners drawing owner pay Sets how many market salaries to deduct
Total owner pay Owner salary and bonus expensed in the P&L above the EBITDA line. Leave out distributions. Starting point for the owner-pay add-back
Market replacement pay per owner What the buyer must pay a physician to do each owner's job Add-back = total owner pay minus (owners x market pay). Negative if owners are underpaid.
Rent adjustment: plus if above market, minus if below market Positive if the practice pays an owner-landlord above market rent. Negative if rent is below market. Added to EBITDA as entered
Low and high multiple Band chosen with the selection table below, or a buyer's written quote EV = adjusted EBITDA x each multiple
Net debt Debt repaid at closing less cash the seller keeps, as your agreement defines both Equity value = EV minus net debt

Three rules to stop double counting:

Outputs: adjusted EBITDA, an enterprise value (EV) range and an equity value range. Equity value comes before escrow, earnout, rollover, any working capital adjustment, fees and taxes. It is not cash.

Not calculated here:

Item Formula on this page What the number means
Escrow Escrow rate x the base named in your agreement Deferred cash, released later if no claims are made
Earnout, expected value Earnout amount x your own probability estimate Undiscounted scenario math, not a present value
Rollover equity Amount rolled into the buyer's entity Illiquid, carried at cost, no cash at close
Fees and taxes Your engagement letters and tax position Carry equity value to the Deal Proceeds Calculator

Enter only add-backs you can document. A rejected add-back is lost at the full multiple.

Setting market pay. The market pay you enter is also what the buyer must pay each physician after closing, so set it the way the buyer will. Use specialty compensation surveys for your region, and check them against official wage data on the BLS Health Care and Social Assistance industry page. Setting market pay too low inflates the add-back, and the buyer's quality of earnings team will reverse it.

Set the Multiple: Size, Specialty, Owner Dependence, Payer Mix and Buyer Type

The calculator takes a low and a high multiple. Five factors decide where they sit. Place size first.

Why size comes first (our reading of FOCUS's 2026 figures). In FOCUS's $5 to $10 million EBITDA column, the provider rows run from 8.8x for multi-specialty practices to 11.3x for plastic surgery, a 2.5-turn spread across specialties at one size. In FOCUS's dermatology table, one step from the small-group band (4x to 7x, midpoint 5.5x) to the regional band (8x to 10x, midpoint 9x) moves the midpoint 3.5 turns (our arithmetic). The two tables sort by different measures (EBITDA in one, revenue in the other), so this is not a controlled comparison. It still shows that a single size step can move the multiple further than the whole specialty spread.

Factor What the 2026 data shows How to set your inputs
1. Size Dermatology multiples rise from 3x to 5x (solo, under $2M revenue) to 12x to 15x ($50M+ revenue or $10M+ EBITDA) (FOCUS dermatology, 2026). FOCUS also reports that healthcare companies above $10M of revenue "often see a 1.5x to 2x jump in valuation multiples" (FOCUS dashboard, 2026). Place your practice by size before anything else. Below $5M of EBITDA, treat FOCUS's 8.8x multi-specialty figure as an upper reference. That cap is our judgment, not a FOCUS figure.
2. Specialty Dermatology has a four-band scale. Multi-specialty practices, plastic surgery and hospitals have one figure each, at $5M to $10M of EBITDA. Use the specialty row if one exists. If not, follow the method for unpublished specialties below.
3. Owner dependence FOCUS describes solo dermatology practices as "owner-dependent" and prices them at 3x to 5x, against 4x to 7x for small groups. If one physician produces most collections with no signed plan to stay, set the low case one band down.
4. Payer mix Buyers favor practices with more than 70% commercial or cash-pay revenue for revenue quality, faster collections and protection from government reimbursement cuts (FOCUS dermatology, 2026). Above 70% supports the top half of your band. A Medicare- or Medicaid-heavy book supports the bottom half. FOCUS publishes no numeric premium, so stay inside the band.
5. Buyer type Corporate buyers in therapeutic and technology-driven sectors paid 20% to 40% higher multiples than financial sponsors on like-for-like EBITDA (FOCUS dashboard, 2026). Model a sponsor case. Add a strategic case at 1.2x to 1.4x the sponsor multiple only if a strategic buyer is in the process. FOCUS measured the premium in those sectors, so applying it to a practice is our assumption.

Why payer mix carries weight. In the CMS National Health Expenditure fact sheet, private health insurance spending was $1,644.6 billion in 2024, 31% of US health spending, and Medicare spending grew 7.8% to $1,118.0 billion, 21% of the total. Commercial rates are negotiated with each plan. Government rates are set by the payer. A buyer underwriting five years of EBITDA prices that difference.

Worked example, buyer type (our arithmetic, our assumption that FOCUS's sector premium carries over). A sponsor prices a practice at 5.0x. Applying FOCUS's 20% to 40% range gives a strategic case of 5.0 x 1.2 = 6.0x to 5.0 x 1.4 = 7.0x. On $1,200,000 of adjusted EBITDA, EV moves from $6,000,000 to between $7,200,000 and $8,400,000.

Worked example, the $10 million revenue line (our arithmetic). FOCUS does not say whether its 1.5x to 2x jump multiplies the multiple or adds turns. On a 4x starting multiple, the multiplier reading gives 6x to 8x and the turns reading gives 5.5x to 6x. FOCUS says "often," and buyers price infrastructure and margin consistency, not a revenue figure. Model the lower reading and treat the jump as a gradient across the $10 million line, not a step at it.

Specialty reference points, 2026

Specialty Published multiple and source 2025 outpatient deal count (PESP via Becker's ASC Review) What to enter
Dermatology 3x to 15x across four revenue bands (FOCUS dermatology, 2026) 24, the most of any outpatient subsector The band from the dermatology table below
Eye care and ophthalmology No band in FOCUS's 2026 pages 22 Unpublished-specialty method below
Oncology No band in FOCUS's 2026 pages 9 Unpublished-specialty method below
Orthopedics, GI, dental No band in FOCUS's 2026 pages Not among the top three subsectors reported Unpublished-specialty method below
Ambulatory surgery centers No band in FOCUS's 2026 pages Not broken out Unpublished-specialty method below
Multi-specialty practices 8.8x at $5M to $10M EBITDA, single benchmark figure (FOCUS dashboard, 2026) Not broken out 8.8x as the high case at that size
Plastic surgery 11.3x at $5M to $10M EBITDA, "highest variance" (FOCUS dashboard, 2026) Not broken out A wide range, because elective demand moves with the economy
Hospitals 9.7x at $5M to $10M EBITDA (FOCUS dashboard, 2026) Hospitals tracked separately below The FOCUS figure at that size

Method for a specialty with no published band. Eye care, orthopedics, GI, dental and ASCs are active buyer markets, and none has a 2026 band in the sources used here. Do not borrow dermatology's scale. Instead:

  1. Start from FOCUS's 8.8x multi-specialty figure if your EBITDA is $5 to $10 million. Below that, set your high case under 8.8x (our judgment, as above).
  2. Move within that range on owner dependence and payer mix, using the factor table.
  3. Replace both inputs with buyers' written multiples as soon as you have them, and ask each buyer to state the multiple and the accepted EBITDA as two separate numbers.

Of the 148 outpatient care deals PESP counted in 2025, 119 were add-on acquisitions (Becker's ASC Review). For most practices, the realistic buyer is an existing platform adding a location. Model that buyer first.

From Benchmarks to Evidence: Replace Published Ranges With Written Bids

FOCUS's figures are banker-published benchmarks with no stated sample size. Damodaran's figures are listed-company multiples. Neither is a closed-deal median for practices like yours. Use them to set a starting range, then replace them with evidence from your own process.

Evidence What to ask for Why it beats a benchmark
Written indications of interest Multiple and accepted adjusted EBITDA as two separate numbers Shows whether a gap is about price or about which add-backs the buyer accepts
Structure terms in each bid Cash at close as a share of price, escrow rate and base, earnout size and metric, rollover share Two bids can differ by hundreds of thousands at close, as the two-offer table below shows
Buyer's recent comparable closings Date, size band and structure of practices the buyer has bought A buyer's own closings are the closest closed-deal data you can get
Comparable sales quoted by peers Date, sample, cash at close and deferred share Last year's headline multiple may predate the drop in the public median (below)
Adviser background The firm's and banker's record on FINRA BrokerCheck A free lookup of registration and disclosure history before you sign an engagement letter

Two or three written bids on the same EBITDA definition tell you more about your price than any published table. Once you have them, enter the lowest and highest written multiples as the calculator's low and high cases.

The 5-Line Bridge: From Adjusted EBITDA to Cash at Close

Enterprise value, equity value and cash at close are three different numbers. The bridge keeps them apart. Each line maps to a worksheet line further down.

  1. Adjusted EBITDA (worksheet line A) = reported EBITDA at the unadjusted margin, plus documented one-time costs from their own field, plus owner pay above market replacement pay for every owner (minus the shortfall if owners are underpaid), plus the rent adjustment (positive if owner rent is above market, negative if below).
  2. Enterprise value (line D) = adjusted EBITDA x the low and high multiples (line C).
  3. Equity value (line F) = EV minus net debt. The calculator stops here.
  4. Escrow (line G) = escrow rate x the base your purchase agreement names. SRS Acquiom reports escrow against "transaction value." Agreements apply the rate to purchase price, EV or equity value, and some carve out contingent consideration. Base rule: an EV base holds back more than an equity base by exactly the escrow rate times net debt. If your LOI does not name a base, ask, and model both until it does.
  5. Cash at close, before fees and taxes (line H) = equity value minus escrow, minus any price deferred into an earnout or rolled into buyer equity.

Sensitivity rule. Each turn of multiple moves enterprise value by one year of adjusted EBITDA. Cash at close moves by less, because escrow, earnout and rollover take their share of every added dollar. On $1.2 million of adjusted EBITDA, going from 5x to 6x adds $1.2 million of EV, and a $100,000 add-back rejected at 6x costs $600,000 of EV (our arithmetic). Document every add-back before you argue about the multiple.

Owner spending is where most add-backs come from. The owner's car, the office build-out and conference travel all sit inside reported EBITDA. Normalize them and back each one with invoices, because the buyer will test every line. The QoE prep checklist sets out the file.

Calculator Run: A Multi-Specialty Practice in FOCUS's $5 to $10 Million Band

Example (invented inputs): a multi-specialty practice has $30,000,000 of revenue and an 18% reported EBITDA margin, entered unadjusted. One-time costs are $0. Three owner physicians draw $2,100,000 in total, expensed in the P&L, against market pay of $500,000 each. Rent is at market, so the rent adjustment is $0. Net debt of $3,000,000 is repaid at closing.

How the multiples were set. Adjusted EBITDA of $6,000,000 sits in FOCUS's $5 to $10 million column, so FOCUS's published 8.8x is the high case. The low case, 7.0x, is our judgment, not a market figure. FOCUS says "density and ancillaries drive premium outcomes," and this practice has no in-house ancillaries, so the low case sits 1.8 turns under the FOCUS figure. The 8.8x already prices a business of this size, so the run adds nothing for the $10 million revenue line.

Step Input or formula Low High
Reported EBITDA $30,000,000 x 18% $5,400,000 $5,400,000
One-time costs Input $0 $0
Owner-pay add-back $2,100,000 minus (3 x $500,000) $600,000 $600,000
Adjusted EBITDA Sum, a 20% margin $6,000,000 $6,000,000
Multiple Input 7.0x (our judgment) 8.8x (FOCUS 2026)
Enterprise value $6,000,000 x multiple $42,000,000 $52,800,000
Net debt Input $3,000,000 $3,000,000
Equity value EV minus net debt $39,000,000 $49,800,000
Escrow at 11.1%, EV base 11.1% x EV $4,662,000 $5,860,800
Cash at close, EV base Equity value minus escrow $34,338,000 $43,939,200
Escrow at 11.1%, equity base 11.1% x equity value $4,329,000 $5,527,800
Cash at close, equity base Equity value minus escrow $34,671,000 $44,272,200
Implied EV/revenue (hand check) EV / $30,000,000 1.40x 1.76x

The 11.1% is SRS Acquiom's median total escrow for 2025 deals without RWI across all sectors, used here as an assumption. Cash at close is before fees, taxes, earnout and rollover. The EV base holds back $333,000 more than the equity base at both ends, which is 11.1% x $3,000,000 of net debt. That gap is 7.5 times the $44,400 gap in the dermatology example below, because this practice carries 7.5 times the net debt. The more net debt, the more the escrow base is worth negotiating.

2026 Multiples Tables: FOCUS Private Benchmarks and Damodaran Public Sectors

FOCUS Investment Banking, 2026 dashboard, private companies with $5M to $10M of EBITDA

Sector EV/EBITDA
Medical practices (multi-specialty) 8.8x
Hospitals 9.7x
Medical device 10.4x
Plastic surgery 11.3x
Medtech (software and digital health) 14.4x

Source: FOCUS Investment Banking, Healthcare EBITDA Multiples: 2026 Dashboard. Each figure is a single published benchmark for that size band, not a closed-deal median with a stated sample.

The dermatology bands sit in their own table below because FOCUS sorts them by revenue, not EBITDA. Do not place a dermatology practice in the EBITDA table or a multi-specialty practice in the revenue table.

Damodaran, US listed companies, EV/EBITDA by sector, data as of January 2026

Sector Firms EV/EBITDA
Hospitals/Healthcare Facilities 31 8.86x
Healthcare Support Services 104 11.17x
Drugs (Pharmaceutical) 228 15.25x
Drugs (Biotechnology) 496 15.78x
Healthcare Products 204 19.78x
Healthcare Information and Technology 115 21.27x
Total market excluding financials 4,822 16.95x

Source: Aswath Damodaran, NYU Stern, EV/EBITDA multiples by sector (US), January 2026. These are listed companies, traded daily and far larger than any practice. They are not private-practice prices.

Public company EV/EBITDA by healthcare industry, US, January 2026 (x EBITDA)
Healthcare IT21.27xHealthcare products19.78xTotal market ex-financials16.95xBiotechnology15.78xPharmaceutical15.25xHealthcare support services11.17xHospitals and facilities8.86x

Public company trading multiples. Private practices usually trade below these.

Chart data
Healthcare IT21.27
Healthcare products19.78
Total market ex-financials16.95
Biotechnology15.78
Pharmaceutical15.25
Healthcare support services11.17
Hospitals and facilities8.86

Source: Aswath Damodaran, NYU Stern, EV/EBITDA by industry, January 2026

Three rules for reading the two tables:

Outer-bound check (our judgment, across different populations). A private buyer prices in illiquidity, key-person risk and payer concentration that a listed company does not carry. If your high multiple exceeds Damodaran's 11.17x for listed Healthcare Support Services companies and your practice is not at platform scale, write down why a buyer would pay more for it than investors pay for listed healthcare services companies. If you cannot, lower the high case. Scale is the exception. FOCUS's 12x to 15x for large dermatology platforms sits above 11.17x, which is why this check flags a high multiple instead of forbidding it.

Dermatology's 4 Size Bands: 3x to 15x EBITDA in 2026

Dermatology led 2025 outpatient deal counts with 24 of PESP's 148 outpatient transactions (Becker's ASC Review). FOCUS's 2026 benchmarks show how far a multiple moves within one specialty. Quoted descriptions are FOCUS's wording.

Band (revenue) EBITDA multiple FOCUS description What moves a practice up a band
Solo, under $2M 3x to 5x "Owner-dependent, limited geographic reach, physician-to-physician deals" A second provider producing a meaningful share of collections
Small group, $2M to $15M 4x to 7x "Broader provider base, mix of medical and cosmetic services, growing buyer pool" Centralized management and in-house ancillaries
Regional platform, $15M to $50M 8x to 10x "Centralized management, in-house pathology and/or Mohs, diversified payor base" Multi-state presence and institutional systems
Large platform, $50M+ or $10M+ EBITDA 12x to 15x "Institutional infrastructure, multi-state presence, and scalable growth play" Top band

Source: FOCUS Investment Banking, Dermatology Practice Valuation: 2026 Benchmarks.

The bands overlap. Solo tops out at 5x and small group starts at 4x. The small-group band covers practices from $2 million to $15 million of revenue, so its top end is 7.5 times its bottom end (our arithmetic), all under one 4x to 7x multiple. Steady margins, diversified collections and more than 70% commercial or cash-pay revenue push toward the top. Lumpy cosmetic revenue or one dominant producer pushes toward the bottom.

Structure at the top. FOCUS reports that platform-ready dermatology practices, typically $5 million or more of EBITDA, get the highest valuations and the most favorable structures, often 70% or more cash at close with meaningful rollover equity. Below that size, plan for a smaller cash share and more escrow or earnout.

Decision rule. If one physician produces most of the collections and has no signed plan to stay after the sale, model the solo band first, whatever the revenue. Model the next band up as the upside case.

Worked Example: A Small Dermatology Group in 2026

Example (invented inputs): a dermatology group has $6,000,000 of revenue, placing it in FOCUS's $2 to $15 million band at 4x to 7x. Reported EBITDA is $900,000, a 15% margin, entered unadjusted. One-time costs are $0. The one owner takes $700,000 in expensed salary against a $450,000 market replacement salary, a $250,000 add-back. The practice pays the owner's real estate entity $50,000 a year above market rent, so the rent adjustment is entered as plus $50,000. Adjusted EBITDA is $900,000 + $250,000 + $50,000 = $1,200,000, a 20% margin. Net debt of $400,000 is paid off at closing.

Bridge line Low (4x) High (7x)
Adjusted EBITDA $1,200,000 $1,200,000
Enterprise value $4,800,000 $8,400,000
Less net debt $400,000 $400,000
Equity value (calculator output) $4,400,000 $8,000,000
No RWI, 11.1% median escrow
Escrow on EV base $532,800 $932,400
Cash at close, EV base $3,867,200 $7,067,600
Escrow on equity base $488,400 $888,000
Cash at close, equity base $3,911,600 $7,112,000
With RWI, 2.8% median escrow
Escrow on EV base $134,400 $235,200
Cash at close, EV base $4,265,600 $7,764,800
Escrow on equity base $123,200 $224,000
Cash at close, equity base $4,276,800 $7,776,000

The escrow rates are SRS Acquiom's medians for 2025 deals across all sectors, used as assumptions. A small practice deal can carry a different holdback. Cash at close is before fees and taxes, and the RWI rows are before the RWI premium. Without RWI, the EV base holds back $44,400 more than the equity base at both ends, exactly 11.1% of the $400,000 net debt. At the high end, RWI moves $697,200 (EV base) or $664,000 (equity base) from deferred cash to cash at close. Whether that trade pays depends on the premium quote.

Owner-dependence case. If buyers price the group in the solo band at 3x to 5x, EV falls to $3,600,000 to $6,000,000. The high end drops $2,400,000 (7x vs 5x) on the same EBITDA. That swing exceeds every escrow line in the table, and it is the clearest reason to add a second producing provider before a sale.

Rent case. The $50,000 rent adjustment assumes the buyer signs a new lease at market. If the owner keeps the building and the buyer takes over the current lease, the adjustment disappears and costs $200,000 to $350,000 of EV at 4x to 7x.

Cash-flow check. EBITDA excludes the lasers, devices and software the group must replace to keep producing. At $150,000 a year of replacements, cash flow before debt service, taxes and working capital is $1,050,000. The $8,400,000 high-end EV is then 8.0x that cash flow, and a buyer applying 7x to cash flow offers $7,350,000. Put three years of equipment spending next to your EBITDA. Check whether any "one-time" cost shows up in each prior year, because a buyer will treat a repeating cost as recurring and strike it from the one-time field.

Two Offers, One Practice: Comparing Price and Structure

Structure is how buyers bridge a price gap. The higher headline often carries more deferred and contingent money, so test every offer on cash at close and on what the earnout is worth to you. The Earnout Value Calculator handles the present-value step.

Assumptions for this example. Same dermatology group, $1,200,000 of adjusted EBITDA, $400,000 of net debt. Headline EV is the full price, including any earnout. Escrow rates are the SRS Acquiom 2025 all-sector medians (2.8% with RWI, 11.1% without). Escrow applies to headline EV, earnout included, unless a row says otherwise. Offer B's 20% earnout is an invented term. Fees, taxes and the RWI premium are excluded. All figures are our arithmetic.

Line Offer A: 5x, RWI, no earnout Offer B: 6x, no RWI, 20% earnout
Headline EV (includes earnout) $6,000,000 $7,200,000
Less net debt $400,000 $400,000
Equity value (includes earnout) $5,600,000 $6,800,000
Escrow (2.8% vs 11.1% of headline EV) $168,000 $799,200
Earnout (20% of headline EV) $0 $1,440,000
Cash at close $5,432,000 $4,560,800

Offer B's headline is $1,200,000 higher, but it pays $871,200 less at close. Three terms produce that gap, and they pull in different directions:

Driver of the gap Effect on Offer B's cash at close vs Offer A
Higher multiple (6x vs 5x on $1,200,000) $1,200,000 more
No RWI: 11.1% vs 2.8% escrow on $7,200,000 $597,600 less
Escrow on the extra $1,200,000 of headline at 2.8% $33,600 less
Earnout (20% of $7,200,000 deferred) $1,440,000 less
Net gap $871,200 less

The earnout alone moves $1,440,000 out of closing. The higher multiple wins back $1,200,000 of it, and the escrow difference takes $631,200. The escrow base changes the total. Bases that include the earnout overstate what Offer B holds back at closing, so the carve-out rows are the fairer test:

Escrow base Offer A escrow Offer B escrow Offer A cash at close Offer B cash at close Gap
Headline EV, earnout included $168,000 $799,200 $5,432,000 $4,560,800 $871,200
Equity value, earnout included $156,800 $754,800 $5,443,200 $4,605,200 $838,000
EV, earnout carved out (B: $5,760,000) $168,000 $639,360 $5,432,000 $4,720,640 $711,360
Equity value, earnout carved out (B: $5,360,000) $156,800 $594,960 $5,443,200 $4,765,040 $678,160

Offer A wins at close on all four bases.

Earnout payout scenarios (undiscounted, assuming both escrows release in full with no claims). Offer A delivers $5,600,000. Offer B delivers $5,360,000 before any earnout.

Share of the $1,440,000 earnout paid Offer B total Compared with Offer A's $5,600,000
0% $5,360,000 $240,000 less
About 16.7% ($240,000) $5,600,000 Break-even
50% $6,080,000 $480,000 more
100% $6,800,000 $1,200,000 more

Escrow-claim scenario (headline EV base, assuming each buyer recovers half its escrow through claims). Offer A falls $84,000 to $5,516,000. Offer B's pre-earnout total falls $399,600 to $4,960,400. Offer B then needs $555,600 of earnout, about 38.6% of it, to break even. The bigger the escrow, the more a claim moves the comparison.

None of these figures discount for time or account for who controls the business during the earnout. Those two factors decide how reachable a payout share is. Get both offers in writing on the same base, ask the higher bidder for a version with less structure at its own price, and choose on cash at close plus the payout share you would bet on.

Escrow in 2025 Deals: SRS Acquiom's Data

Escrow measure, 2025 deals, all sectors Average Median
General indemnification escrow, no RWI 11.3% 10.0%
General indemnification escrow, with RWI 2.2% 0.5%
Total escrow, no RWI 14.7% 11.1%
Total escrow, with RWI 5.1% 2.8%

Source: SRS Acquiom, 2026 Deal Terms for M&A Escrows, 2025 deals in SRS Acquiom's M&A dataset, as a percentage of transaction value.

RWI shrinks the escrow but rarely removes it. In the same 2025 data, 92% of deals with RWI still carried an indemnification escrow or holdback, against 84% of deals without RWI. In every row the average sits above the median, so a tail of large holdbacks pulls the average up. Benchmark a proposed escrow against the median.

Ask the buyer before you accept a headline number:

The LOI and term sheet red flags checklist covers the drafting traps, and the healthcare deal structures guide covers earnout and rollover mechanics.

The Public Median Fell From 14.5x to 11.5x: What It Means for Private Bids

FOCUS's 2026 dashboard reports that the median EV/EBITDA multiple for publicly traded healthcare services companies "declined to approximately 11.5x in 2026, down from 14.5x the prior year." That is a drop of 3 turns, or about 20.7% (our arithmetic, on FOCUS's rounded figures).

FOCUS reports three other public figures, each on a different measure, population or date. Read each on its own:

FOCUS figure Population and date Value
Median EV/EBITDA, public healthcare services FOCUS's public set, as reported in its 2026 dashboard About 11.5x, down from 14.5x the prior year
Median TEV/EBITDA, public healthcare operators Public comps, Q2 2025 12.4x
Share of EV growth from multiple expansion Public healthcare operators, Q2 2025 About 68%
Operators with higher implied forward multiples Public operators, July to August 2025 13 of 16

What it means for a seller:

Copy-Ready Worksheet: 8 Lines, Each With Its Formula and Source

Copy this into a spreadsheet. Fill column 2 from your records and each written offer. Column 4 is what you cite when a buyer asks where a number came from. The letters match the bridge above and the diligence table below.

Line Your figure Formula Benchmark to cite, with date
A. Adjusted EBITDA Reported EBITDA at the unadjusted margin + one-time costs (own field) + owner-pay add-back + rent adjustment (plus if above market, minus if below) Your add-back file
B. Annual equipment and software replacement Three-year average from your books Your records
C. Low and high multiple Size first, then specialty, owner dependence, payer mix and buyer type FOCUS 2026 dashboard or FOCUS dermatology 2026, or a buyer's written quote
D. Enterprise value A x C Calculator output
E. Cash-flow multiple implied D / (A minus B) Cash-flow check above
F. Equity value D minus net debt Calculator output
G. Escrow Rate x the base in the LOI (run EV and equity bases if unstated, with and without contingent consideration) SRS Acquiom 2026 escrow report, 2025 deals, all sectors
H. Cash at close before fees and taxes F minus G minus earnout minus rollover Carry to the Deal Proceeds Calculator

Keep earnout and rollover in their own rows. Treat the earnout as undiscounted scenario math and carry rollover at cost with no cash at close.

What Buyers Verify: 7 Items and Why Each Moves the Multiple

A buyer applies its multiple only to EBITDA it can verify. Each gap lands on a worksheet line. The full request list is in the buyer due diligence checklist.

Item to prepare Red flag if missing Worksheet line it hits
Financials, ideally reviewed or audited, with monthly detail that ties to tax returns Buyer cannot confirm reported EBITDA Line C (lower multiple) and line G (larger escrow)
Add-back file with payroll records, leases and invoices Undocumented add-backs get rejected Line A, multiplied by the full multiple
Three years of equipment and software spending Buyer prices on cash flow instead of EBITDA Line B, as in the cash-flow check above
Revenue by payer, with renewal dates A large contract near renewal is a future-EBITDA risk, and a government-heavy mix forfeits the commercial-pay preference Line C, or an earnout that reduces line H
Collections by provider Concentration in the owner points to the solo band Line C, as in the $2,400,000 owner-dependence case above
Ancillary revenue (pathology, imaging, Mohs) shown separately Buyer cannot credit what FOCUS calls premium drivers Line C
Compliance file Referral or ownership problems surface in diligence Line G (special indemnity or escrow), or a failed deal

Seller preparation order (our recommendation). Fix the items that hit line A first, because every rejected dollar is lost at the full multiple. Then build the provider and payer reports that support line C. Escrow and structure terms come last, once a buyer has accepted your EBITDA.

Before You Sign an LOI: Seven Terms Ranked by Their Swing in the Dermatology Example

An LOI fixes most of the numbers that decide cash at close. The table ranks the terms by the dollar swing each one produced in the dermatology group above ($1,200,000 of adjusted EBITDA, $400,000 of net debt). Settle the largest ones in writing before you sign. All figures are our arithmetic from the dermatology examples on this page.

Term to pin down Question to settle in the LOI Swing in the dermatology example Where it is worked
Size band and owner dependence Which band is the buyer pricing, and what retention plan supports it? $2,400,000 of EV at the high end (7x vs 5x) Owner-dependence case
Earnout share How much of the headline sits in an earnout, on what metric? $1,440,000 of Offer B's price moved from closing into contingent pay Gap breakdown in the two-offer section
Cash-flow vs EBITDA pricing Is the multiple applied to EBITDA or to EBITDA after equipment spending? $1,050,000 of EV ($8,400,000 vs $7,350,000) Cash-flow check
RWI Will the buyer use RWI, and who pays the premium? $697,200 moved to cash at close at 7x (EV base) Worked example table
Each accepted add-back Which add-backs does the buyer accept, stated as a separate EBITDA figure? $600,000 of EV per $100,000 rejected at 6x Sensitivity rule
Rent treatment Will the buyer sign a new lease at market or keep the current one? $200,000 to $350,000 of EV Rent case
Escrow base Does escrow apply to EV or equity value, with or without the earnout? $44,400 at 11.1% (EV vs equity base) Worked example table

How to use it. Run the calculator once for each written bid, then fill a column per bid with that buyer's answer to each question. A bid that leaves the top three rows open is not yet comparable to one that answers them. The sale readiness guide sets the order of work in the months before bids arrive.

The Seven LOI Terms Scored for Offer A and Offer B

Here is the scorecard filled in for the two offers above, using only figures already on this page. Each "exposure" cell shows what the term could cost that offer if the buyer's position moves against you. All figures are our arithmetic.

Term Offer A: 5x, RWI, no earnout Offer B: 6x, no RWI, 20% earnout Exposure, A vs B
Size band and owner dependence 5x, the top of the solo band and inside the small-group band 6x, above the solo band's 5x ceiling A: none if repriced to the solo top. B: $1,200,000 of EV if repriced to 5x
Earnout share $0 $1,440,000 deferred B only: the full $1,440,000 depends on the metric and on who runs the business
Cash-flow vs EBITDA pricing Priced on EBITDA Priced on EBITDA If either buyer moves to $1,050,000 of cash flow: A loses $750,000 of EV, B loses $900,000
RWI Yes, 2.8% escrow, $168,000 No, 11.1% escrow, $799,200 B holds back $631,200 more
Each accepted add-back $500,000 of EV per $100,000 rejected $600,000 of EV per $100,000 rejected Every rejected add-back costs B one-fifth more
Rent treatment $50,000 adjustment worth $250,000 of EV $50,000 adjustment worth $300,000 of EV Both lose it if the current lease carries over
Escrow base $11,200 gap between EV and equity base $44,400 gap between EV and equity base, and $159,840 more if the earnout is not carved out of the EV base B gains more from negotiating the base
Cash at close, headline EV base $5,432,000 $4,560,800 A leads by $871,200

Reading the scorecard. Offer B's higher multiple raises its exposure on every row that scales with the multiple (add-backs, rent, cash-flow pricing), and it carries the only earnout. Before treating B as the better offer, ask its buyer to confirm in writing which add-backs it accepts, whether it prices on EBITDA, and what retention plan supports a 6x multiple. If those three answers come back favorable and you would bet on at least the 16.7% break-even payout, B can still come out ahead over time. Otherwise A is the stronger bid.

Post-closing physician pay, rollover equity and any management services structure raise questions covered in the healthcare compliance due diligence guide and the management services organizations guide, and deal size or location can bring in reviews covered in the healthcare M&A process guide. Take the questions those pages raise to your own attorney before the LOI fixes the structure, because the answers can change the structure or the timetable.

Who Buys Practices Now: Platforms, Hospitals and Other Physicians

Where US physicians worked in 2024, by practice ownership (% of physicians)
Private practice (physician-owned)42.2%Hospital-owned practice34.5%Directly employed by hospital12.2%Private equity-owned practice6.5%
Chart data
Private practice (physician-owned)42.2
Hospital-owned practice34.5
Directly employed by hospital12.2
Private equity-owned practice6.5

Source: American Medical Association, Physician Practice Benchmark Survey 2024

The chart shows physician employment by practice ownership from the AMA's 2024 Physician Practice Benchmark Survey. It counts where physicians work, not bids or multiples. The deal data below shows who is buying.

Buyer group 2025 and 2026 activity Source
PE-backed outpatient platforms 148 outpatient care deals in 2025, 119 of them add-ons PESP 2025 data via Becker's ASC Review
Hospital acquirers 22 transactions announced in Q1 2026, 18 in Q2 and 16 in Q3, for 56 through Q3 against 46 in all of 2025 Kaufman Hall data via Becker's Hospital Review

Kaufman Hall's 46 transactions in 2025 were its lowest annual count since it began tracking hospital transactions in 2011. Its counts cover hospital transactions, not physician practice purchases. They show hospital systems doing more deals in 2026, not more practice bids. Each buyer group prices owner dependence, payer mix and earnout risk differently. Model at least two of them, as in the two-offer table, and compare cash at close, not headline value.

Buyer type What it typically weighs most How to model it here
PE-backed platform adding a location Documented EBITDA, payer mix, provider retention Sponsor case at your band, with escrow and rollover lines
Strategic or corporate buyer Fit with its services and technology Sponsor multiple x 1.2 to 1.4, only if one is bidding (FOCUS 2026 sector premium, applied to practices as our assumption)
Hospital system Referral base and market position Separate case, with post-closing physician pay set at market
Physician buyer or partner buy-in Owner's production and transition Solo or small-group band, with more seller financing and no rollover. The SBA 7(a) program sets a loan limit that can change, which limits what one physician buyer can finance through it. Confirm the current limit with the lender.

Worked example, physician buyer (our arithmetic, invented inputs). A solo practice with $600,000 of adjusted EBITDA at 4x has an EV of $2,400,000. A small group with $1,200,000 at 5x has an EV of $6,000,000. Confirm the current 7(a) loan limit with the lender. If the price exceeds it, the buyer needs the difference from seller financing, its own equity or other lenders. If your realistic buyer is another physician, size that gap before you set your price expectation.

Questions Practice Owners and Investors Ask

What multiple of EBITDA does a medical practice sell for in 2026?

FOCUS Investment Banking's 2026 dashboard gives 8.8x for multi-specialty medical practices with $5 to $10 million of EBITDA. That is a single published benchmark figure, not a closed-deal median. Smaller practices sell for less. FOCUS's 2026 dermatology benchmarks price small groups with $2 to $15 million of revenue at 4x to 7x and solo practices under $2 million of revenue at 3x to 5x. Place your practice by size first, then adjust for specialty, owner dependence, payer mix and buyer type.

How much is a dermatology practice worth?

Multiply adjusted EBITDA by the FOCUS 2026 band that fits. Solo practices under $2 million of revenue trade at 3x to 5x. Small groups with $2 to $15 million trade at 4x to 7x. Regional platforms with $15 to $50 million trade at 8x to 10x, and platforms with $50 million or more of revenue or $10 million or more of EBITDA trade at 12x to 15x. Example (our arithmetic): $1.2 million of adjusted EBITDA at small-group multiples gives $4.8 to $8.4 million of enterprise value, before net debt, escrow, fees and taxes.

Do strategic buyers pay more than private equity for a healthcare business?

FOCUS Investment Banking's 2026 dashboard found that corporate buyers in therapeutic and technology-driven sectors paid 20% to 40% higher multiples than financial sponsors on a like-for-like EBITDA basis. FOCUS measured that for those sectors, not for physician practices, so apply it to a practice only when a strategic buyer is actually bidding. Private equity competes on structure as well as price. FOCUS reports that platform-ready dermatology practices, typically $5 million or more of EBITDA, often receive 70% or more of the price in cash at close plus meaningful rollover equity.

How much of the sale price is held back in escrow when I sell my practice?

SRS Acquiom's 2026 Deal Terms for M&A Escrows covers 2025 deals across its M&A dataset in all sectors, not practice sales alone. Deals without reps and warranties insurance (RWI) had a median total escrow of 11.1% of transaction value. Deals with RWI had a median of 2.8%. Escrow is deferred cash, released later if no claims are made. Your purchase agreement sets the rate, the base it applies to and the release dates.

Does crossing $10 million of revenue raise my multiple?

FOCUS reports that companies above $10 million of annual revenue often see a 1.5x to 2x jump in valuation multiples, as buyers price in infrastructure maturity and margin consistency. The figure covers healthcare companies generally, not one specialty. FOCUS does not say whether the jump multiplies the multiple or adds turns. On a 4x starting multiple, a multiplier reading gives 6x to 8x and a turns reading gives 5.5x to 6x (our arithmetic). Treat it as a direction, not a step at an exact revenue line.

Where do one-time costs go in the calculator?

In the one-time costs field only. Enter your reported EBITDA margin exactly as your financial statements show it, with no adjustment, and enter each documented one-time cost in its own field. If you also raise the margin to strip those costs out, you count them twice and overstate value by the cost times the multiple.

Can a physician buyer use an SBA loan to buy my practice?

Yes, if the buyer qualifies. The SBA's 7(a) program is its main small business loan program, and the program sets a loan limit that can change, so confirm the current limit with the lender. That limit restricts how much of a price a single physician buyer can finance through 7(a), so physician-to-physician deals at larger sizes usually add seller financing or buyer equity.

Sources